

BMJ Open

Optimal plateau pressure for patients with acute respiratory distress syndrome: A protocol for a systematic review and meta-analysis.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-015091
Article Type:	Protocol
Date Submitted by the Author:	10-Nov-2016
Complete List of Authors:	Yasuda, Hideto; Kameda Medical Center, Department of Intensive Care Medicine; Keio University School of Medicine, Department of Preventive Medicine and Public Health Nishimura, Tetsuro; National Hospital Organization Osaka National Hospital, Traumatology and Critical Care Medical Center Kamo, Tetsuo; Osaka City University Graduate School of Medicine, Department of Traumatology and Critical Care Medicine Sanui, Masamitsu; Jichi Medical University, Department of Anesthesiology and Critical Care Medicine Nango, Eishu; Tokyo-Kita Medical Center, Department of General Medicine Abe, Takayuki; Keio University Hospital Takebayashi, Toru; Keio University School of Medicine, Department of Preventive Medicine and Public Health Lefor, Alan; Jichi Medical University, Department of Surgery Hashimoto, Satoru; Kyoto Prefectural University of Medicine, Department of Anesthesiology and Intensive Care Medicine
Primary Subject Heading:	Respiratory medicine
Secondary Subject Heading:	Evidence based practice
Keywords:	acute respiratory distress syndrome, ARDS, mechanical ventilation, plateau pressure

SCHOLARONE™
Manuscripts

Title

Optimal plateau pressure for patients with acute respiratory distress syndrome: A protocol for a systematic review and meta-analysis.

Registration

Protocol and registration: We registered this protocol to this journal and PROSPERO (registration number is: CRD42016041924).

Authors

Hideto Yasuda, MD^{1,2}, Tetsuro Nishimura, MD³, Tetsuro Kamo, MD⁴, Masamitsu Sanui, MD, PhD⁵, Eishu Nango, MD⁶, Takayuki Abe, PhD^{2,7}, Toru Takebayashi, MD, PhD², Alan Kawarai Lefor MD MPH PhD⁸ and Satoru Hashimoto, MD, PhD⁹

1. Department of Intensive Care Medicine, Kameda Medical Center, Chiba, Japan
2. Department of Preventive Medicine and Public Health, Keio University School of Medicine, Tokyo, Japan
3. Department of Traumatology and Critical Care Medicine, Osaka City University

1
2
3
4
5
6 Graduate School of Medicine, Osaka, Japan
7
8

9
10 4. Department of Respiratory Medicine, Keio University School of Medicine, Tokyo,
11
12 Japan
13

14
15 5. Department of Anesthesiology and Critical Care Medicine, Jichi Medical University
16
17 Saitama Medical Center, Saitama, Japan
18
19

20
21 6. Department of General Medicine, Tokyo-Kita Medical Center, Tokyo, Japan
22
23

24
25 7. Biostatistics Unit at Clinical and Translational Research Center, Keio University
26
27 Hospital, Tokyo, Japan
28
29

30
31 8. Department of Surgery, Jichi Medical University, Tochigi, Japan
32
33

34
35 9. Department of Anesthesiology and Intensive Care, Kyoto Prefectural University of
36
37 Medicine, Kyoto, Japan
38
39

40
41
42
43
44 **Corresponding author**

45
46 Satoru Hashimoto, Department of Anesthesiology and Intensive Care, Kyoto Prefectural
47
48 University of Medicine, Kyoto, Japan
49
50

51
52 Kawaramachi-Hirokoji Kajii-cho 465, Kamigyo, Kyoto, Japan 602-8566
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Phone 81/75-251-5725 FAX 81/75-251-5843

satoru@koto.kpu-m.ac.jp

Key words: acute respiratory distress syndrome, ARDS, mechanical ventilation, plateau pressure

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2016-015091 on 29 May 2017. Downloaded from <http://bmjopen.bmj.com/> on April 17, 2024 by guest. Protected by copyright.

Abstract

Introduction: Lower tidal volume ventilation in patients with acute respiratory distress syndrome (ARDS) and low lung compliance is one strategy to reduce the plateau pressure in order to prevent ventilator induced lung injury (VILI). Several randomized controlled trials (RCTs) and meta-analyses showed that limiting both the plateau pressure and the tidal volume decreased mortality, but the optimal plateau pressure to demonstrate a benefit is uncertain. The aim of this systematic review is to investigate the optimal upper limit of plateau pressure in patients with ARDS to prevent VILI and improve clinical outcomes.

Methods and analysis: RCTs comparing two mechanical ventilation strategies will be included, with lower plateau pressure and with higher plateau pressure, among patients with ARDS and acute lung injury. Data sources include MEDLINE via the NCBI Entrez system, Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE and Ichushi, a database of papers in Japanese. Two of three physicians will independently screen trials obtained by search for eligibility, and extract data from included studies onto standardized data recording forms. For each included trial, the risk of bias and the

1
2
3
4
5
6 quality of evidence will be evaluated using the Grading of Recommendation
7
8
9 Assessment Development and Evaluation (GRADE) system.
10

11
12 **Ethics and dissemination:** This systematic review and meta-analysis does not require
13
14 ethical approval. The results of this systematic review and meta-analysis will be
15
16 disseminated through conference presentation and publication in a peer-reviewed
17
18
19
20
21
22 journal.
23

24
25 **Trial registration number:** CRD42016041924
26
27

28 29 30 31 32 **Strengths and limitations of this study** 33

- 34
- 35 1. This is the first systematic review comparing different plateau pressures and
36
37 investigating the upper limit of plateau pressure for patients with ARDS
38
39 undergoing mechanical ventilation to prevent ventilator induced lung injury.
40
41
42
43
 - 44 2. This systematic review will only compare clinical outcomes among different plateau
45
46 pressures, but it will also be important to compare the trans-pulmonary pressure
47
48 using different mechanical ventilation strategies.
49
50
51
 - 52 3. This is a protocol article. The results of the subsequent systematic review and
53
54
55
56
57
58
59
60

meta-analysis will be prepared separately.

For peer review only

Introduction

Acute respiratory distress syndrome (ARDS) is a common life-threatening disorder in critically ill patients with 30-60% mortality (1-3). ARDS is usually accompanied by short- and long-term morbidities including prolonged stay in the intensive care unit, prolonged ventilator dependence, various neuropsychological impairments (e.g. depression, cognitive decline) and decreased quality of life (2, 4, 5).

The most critical factor associated with the high mortality in patients with ARDS is ventilator induced lung injury (VILI)(6). Patients with ARDS and low lung compliance receiving mechanical ventilation may develop VILI, including regional alveolar over-distension, repetitive cycling alveolar collapse with shear stress (atelectrauma) aggravated by a high concentration of inspired oxygen, (7-10). VILI can lead to not only an extended time needed for liberation from mechanical ventilation, but also an increase in mortality.

For the purpose of minimizing VILI, a substantial number of ventilator strategies have been proposed (11-15). Lower tidal volume (6 ml/kg per predicted body weight) ventilation is a strategy to reduce plateau pressure, the airway pressure during

1
2
3
4
5
6 the end-expiratory pause, roughly reflecting the level of alveolar over-distension (13).
7
8

9
10 Several randomized controlled trials (RCTs) and meta-analyses have shown a beneficial
11
12 effect of pressure and volume-limited ventilation strategies on clinical outcomes in
13
14 patients with ARDS (13, 14, 16-23). In the Scandinavian clinical practice guideline
15
16 2014(17), created using a Cochrane systematic review (16), it is strongly recommended
17
18 that airway pressure and tidal volume should be limited. In the Surviving Sepsis
19
20 Campaign Guideline 2012 (24), it is recommended that plateau pressure should be
21
22 measured and maintained below 30cmH₂O during the time of passive pulmonary
23
24 expansion. However, these previously published studies and guidelines failed to clearly
25
26 show an optimal upper limit for plateau pressure. A recent meta-analysis comparing two
27
28 different ventilator strategies conducted in a Cochrane review (16) was a comparison
29
30 between two lung protective ventilator strategies, not a comparison of different cutoff
31
32 limits of plateau pressures.
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47
48 Therefore, we will conduct a meta-analysis and systematic review to
49
50 investigate the optimal plateau pressure for patients with ARDS.
51
52
53
54
55
56
57
58
59
60

Objective

The objective of this systematic review is to investigate the optimal limit of plateau pressure to improve clinical outcomes associated with VILI in patients with ARDS.

Methods and analyses

This systematic review is designed following the Preferred Reporting Items for Systematic review and Meta-Analyses (PRISMA) statements (25). The logistics and reporting of this protocol will be in compliance with the PRISMA-P. This protocol is registered with PROSPERO prospective register of systematic reviewers (registration number is: CRD42016041924).

Study Eligibility

Type of studies: We will include only published RCTs, either full scale or as pilot studies.

Type of participants: The study will include adults with ARDS or acute lung injury (ALI) from any cause, as defined by the North-American-European Consensus

1
2
3
4
5
6 Conference on ARDS (NAECC), age 18years or older, undergoing mechanical
7
8
9 ventilation (26).
10

11
12 **Type of interventions and comparators:** We will include RCTs which compared
13
14 two different mechanical ventilation strategies, with a lower plateau pressure and a
15
16 higher plateau pressure, among patients with ARDS and ALI.
17
18
19

20
21 **Type of outcomes:** The following outcome measures will be evaluated: the primary
22
23 outcome is mortality (1. at the end of the follow up period for each trial, 2. at day 28,
24
25 and 3. at the hospital discharge), and secondary outcomes are the number of
26
27 ventilator-free days up to 28 days and barotrauma during hospitalization.
28
29
30
31
32

33 34 35 **Information sources**

36
37 We searched MEDLINE via the NCBI Entrez system, the Cochrane Central
38
39 Register of Controlled Trials (CENTRAL), EMBASE and Ichushi, a database including
40
41 papers in Japanese.
42
43
44
45
46

47 48 **Search strategy**

49
50 We used the search keywords “Mechanical ventilation” AND “ARDS”, “adult
51
52 respiratory distress syndrome”, “ALI” or “acute lung injury” AND “Tidal volume”,
53
54
55
56
57
58
59
60

1
2
3
4
5
6 “pressure limited” or “volume limited”. We also performed a MeSH term search using
7
8
9
10 the following terms: “respiratory distress syndrome, adult”, or “acute lung injury” AND
11
12
13 “tidal volume”, or “respiration, artificial”. Searches were performed in May or June
14
15
16 2016. The detailed strategy and details of the dates performed are shown in Table 1.
17

18 19 **Study records and Data management**

20
21
22 The literature search results from each database will be extracted into
23
24
25 Microsoft (Redmond WA USA) Excel files and duplicates will be removed by being
26
27
28 sorted alphabetically based on author. The results of all processes (first screening and
29
30
31 second screening) are recorded to the same data file. All full text files will be managed
32
33
34 with EndNote (X7) bibliographic software (Thompson Reuters, Philadelphia,
35
36
37 Pennsylvania, USA). A meta-analysis will be conducted with the Review Manager
38
39
40 (RevMan) software V.5.3.5. All data will be managed by the primary investigator HY.
41
42
43
44

45 **Selection process**

46
47
48 Two of three physicians (HY, TN, TK) will screen titles and abstracts during
49
50
51 the first screening and the full text during the second screening for relevant studies, and
52
53
54 will independently extract data from included studies into standardized data forms.
55
56
57
58
59
60

1
2
3
4
5
6 Disagreements are resolved by discussion with one of the three physicians who did not
7
8
9
10 screen the study. EN supervises the process of systematic review. TA supervises the
11
12
13 process of analysis as a biostatistician. MS, TT and SH are consultants on clinically
14
15
16 relevant issues.
17

18 19 **Data collection process**

20
21
22 After extracting studies for meta-analyses during the second screening, data
23
24
25 will be extracted from each study by three reviewers (HY, TN, TK) using two tools: (1)
26
27
28 the Cochrane Data Collection Form (RCTs only) (27) and (2) Review Manager
29
30
31 (RevMan) software V.5.3.5(28).
32
33

34 35 **Risk of bias in individual studies**

36
37
38 The risk of bias in each included study will be evaluated with the Cochrane
39
40
41 Risk of Bias Assessment tool (29, 30) with respect to the following eight domains: (a)
42
43
44 random sequence generation, (b) allocation concealment, (c) blinding of participants
45
46
47 and personnel, (d) blinding of outcome assessors, (e) incomplete outcome data, (f)
48
49
50 selective outcome reporting and (g) other sources of bias. Each bias will be graded as
51
52
53 either 'low-risk', 'unclear-risk' or 'high-risk'. Two of three reviewers (HY, TN, TK) will
54
55
56
57
58
59
60

1
2
3
4
5
6 separately grade the bias of each study, and any disagreement will be resolved by a
7
8
9
10 decision from the remaining reviewer.

11 12 13 **Data synthesis**

14
15 Forest plots will be used for the meta-analysis, and effect size will be
16
17 expressed as relative risk with 95% confidence interval [CI] for categorical data and as
18
19 weighted mean differences with 95% CI for continuous data. Outcome measures will be
20
21 pooled using a random effect model because of anticipated significant heterogeneity in
22
23 included studies. For all analyses, a two-sided p-value < 0.05 is considered significant.
24
25
26
27
28
29
30
31
32 In case of missing data, we will attempt to contact the authors of the study for additional
33
34
35 data. If a reply from the authors is not obtained, we will classify it as missing data.
36
37

38 39 **Assessment of heterogeneity**

40
41 Study heterogeneity between trials for each outcome will be assessed with an
42
43 I^2 statistic for quantifying inconsistency (RevMan). I^2 values of <25%, 25%-50% and
44
45 >50% represent small, medium and large amounts of heterogeneity, respectively (31).
46
47
48
49
50
51 Subgroup analysis and sensitivity analysis will be performed for evaluating possible
52
53
54
55 sources of heterogeneity.
56
57
58
59
60

Assessment of reporting bias

A funnel plot will be used to investigate the possibility of publication bias if ≥ 10 studies are available (RevMan) (32). To test for funnel plot asymmetry, we will use the Egger test (33) for continuous outcomes and the arcsine test (34) for dichotomous outcomes.

Subgroup analysis and sensitivity analysis

Subgroup analysis is planned based on the main factors that may cause heterogeneity, which are the levels of plateau pressure. Subgroup analysis will also be performed for different timing of plateau pressure measured during mechanical ventilation. We are also planning subgroup analyses after stratification according to ventilator strategies and modes.

For sensitivity analysis, we will first exclude all studies that are assessed as having a high risk of bias. High risk of bias in each study will be determined when the quality of evidence of each study will be assessed as “low” or “very low”. The remaining studies will be used for sensitivity analysis.

Assessment of confidence in cumulative evidence

We will evaluate the quality of evidence for these studies, using the Grading of Recommendation Assessment Development and Evaluation (GRADE) system (35). The quality of evidence will be decreased by any one of the following limitations: risk of bias, imprecision, inconsistency, indirectness and publication bias. Based on this assessment, the quality of evidence for each outcome will be assessed as 'high', 'moderate', 'low' or 'very low' (GRADEpro, McMaster University, 2014). Two of three reviewers (HY, TN, TK) will separately grade the quality of evidence of each study, and any disagreement will be resolved by a decision of the remaining reviewer.

Authors' contributions

HY contributed in the study concept and design, screening for relevant studies, and drafting of the manuscript. TN and TK contributed to the study concept and design, screening for relevant studies. MS contributed to the study concept and design, and critical revision of the manuscript for important intellectual content. AL contributed to critical revision of the manuscript for important intellectual content. EN supervised the process of systematic review. TA supervised the process of analysis as a biostatistician. TT, AL and SH were consultants on clinically relevant issues.

Funding sources/sponsors

None

Conflicts of interest

No one has conflicts of interest in the study.

References

1. Rubenfeld GD, Caldwell E, Peabody E, *et al.* Incidence and outcomes of acute lung injury. *N Engl J Med* 2005;353:1685-93.
2. Rubenfeld GD, Herridge MS. Epidemiology and outcomes of acute lung injury. *Chest* 2007;131:554-62.
3. Bersten AD, Edibam C, Hunt T, *et al.* Incidence and mortality of acute lung injury and the acute respiratory distress syndrome in three Australian States. *Am J Respir Crit Care Med* 2002;165:443-8.
4. Herridge MS, Tansey CM, Matte A, *et al.* Functional disability 5 years after acute respiratory distress syndrome. *N Engl J Med* 2011;364:1293-1304.
5. Davidson TA, Caldwell ES, Curtis JR, *et al.* Reduced quality of life in survivors of acute respiratory distress syndrome compared with critically ill control patients. *JAMA* 1999;281:354-60.
6. Amato MB, Meade MO, Slutsky AS, *et al.* Driving pressure and survival in the acute respiratory distress syndrome. *N Engl J Med* 2015;372:747-55.
7. Gattinoni L, Pesenti A, Avalli L, *et al.* Pressure-volume curve of total respiratory system in acute respiratory failure. Computed tomographic scan study. *Am Rev Respir Dis* 1987;136:730-6.
8. Dreyfuss D, Soler P, Basset G, *et al.* High inflation pressure pulmonary edema. Respective effects of high airway pressure, high tidal volume, and positive end-expiratory pressure. *Am Rev Respir Dis* 1988;137:1159-64.
9. Muscedere JG, Mullen JB, Gan K, *et al.* Tidal ventilation at low airway pressures can augment lung injury. *Am J Respir Crit Care Med* 1994;149:1327-34.
10. Caironi P, Cressoni M, Chiumello D, *et al.* Lung opening and closing during ventilation of acute respiratory distress syndrome. *Am J Respir Crit Care Med* 2010;181:578-86.
11. Ferguson ND, Cook DJ, Guyatt GH, *et al.* High-frequency oscillation in early acute respiratory distress syndrome. *N Engl J Med* 2013;368:795-805.
12. Young D, Lamb SE, Shah S, *et al.* High-frequency oscillation for acute respiratory distress syndrome. *N Engl J Med* 2013;368:806-13.
13. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung

- injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. *N Engl J Med* 2000;342:1301-08.
14. Meade MO, Cook DJ, Guyatt GH, et al. Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. *JAMA* 2008;299:637-45.
 15. Kacmarek RM, Villar J, Sulemanji D, et al. Open Lung Approach for the Acute Respiratory Distress Syndrome: A Pilot, Randomized Controlled Trial. *Crit Care Med* 2016;44:32-42.
 16. Petrucci N, De Feo C. Lung protective ventilation strategy for the acute respiratory distress syndrome. *Cochrane Database Syst Rev* 2013:CD003844.
 17. Claesson J, Freundlich M, Gunnarsson I, et al. Scandinavian clinical practice guideline on mechanical ventilation in adults with the acute respiratory distress syndrome. *Acta Anaesthesiol Scand* 2015;59:286-97.
 18. Fuller BM, Mohr NM, Drewry AM, et al. Lower tidal volume at initiation of mechanical ventilation may reduce progression to acute respiratory distress syndrome: a systematic review. *Crit Care* 2013;17:R11.
 19. Burns KE, Adhikari NK, Slutsky AS, et al. Pressure and volume limited ventilation for the ventilatory management of patients with acute lung injury: a systematic review and meta-analysis. *PLoS One* 2011;6:e14623.
 20. Moran JL, Bersten AD, Solomon PJ. Meta-analysis of controlled trials of ventilator therapy in acute lung injury and acute respiratory distress syndrome: an alternative perspective. *Intensive Care Med* 2005;31:227-35.
 21. Brochard L, Roudot-Thoraval F, Roupie E, et al. Tidal volume reduction for prevention of ventilator-induced lung injury in acute respiratory distress syndrome. The Multicenter Trail Group on Tidal Volume reduction in ARDS. *Am J Respir Crit Care Med* 1998;158:1831-8.
 22. Brower RG, Shanholtz CB, Fessler HE, et al. Prospective, randomized, controlled clinical trial comparing traditional versus reduced tidal volume ventilation in acute respiratory distress syndrome patients. *Crit Care Med* 1999;27:1492-8.
 23. Villar J, Kacmarek RM, Perez-Mendez L, et al. A high positive

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- end-expiratory pressure, low tidal volume ventilatory strategy improves outcome in persistent acute respiratory distress syndrome: a randomized, controlled trial. *Crit Care Med* 2006;34:1311-8.
24. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. *Intensive Care Med* 2013;39:165-228.
25. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ* 2015;349:g7647.
26. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. *Am J Respir Crit Care Med* 1994;149:818-24.
27. Collaboration. TC. Data Collection Form-Intervention review for RCTs only. Secondary Data Collection Form-Intervention review for RCTs only.
<<http://training.cochrane.org/resource/data-collection-forms-intervention-reviews>> Accessed 7 November 2016
28. Collaboration. TC. RevMan 5 Download and Installion. Secondary RevMan 5 Download and Installion.
<<http://tech.cochrane.org/revman/download>>Accessed 7 November 2016
29. Collaboration. TC. Cochrane Handbook for Systematic Reviews of Interventions.
<<http://training.cochrane.org/handbook> > Accessed 7 November 2016
30. Collaboration. TC. Table 8.5.d: Criteria for judging risk of bias in the 'Risk of bias' assessment tool.
<http://handbook.cochrane.org/chapter_8/table_8_5_d_criteria_for_judging_risk_of_bias_in_the_risk_of.htm >Accessed 7 November 2016
31. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;21:1539-58.
32. Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. *BMJ* 2011;343:d4002.

- 1
2
3
4
5
6 33. Davey Smith G, Egger M. Meta-analyses of randomised controlled trials.
7 *Lancet* 1997;350:1182.
8
9 34. Rucker G, Schwarzer G, Carpenter J. Arcsine test for publication bias in
10 meta-analyses with binary outcomes. *Stat Med* 2008;27:746-63.
11
12 35. Guyatt GH, Oxman AD, Schunemann HJ, *et al.* GRADE guidelines: a new
13 series of articles in the Journal of Clinical Epidemiology. *J Clin Epidemiol*
14 2011;64:380-2.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 Search strategy

1. MEDLINE

Performed on 2016/05/17

Number	Searched for
Component 1. Included patients	
#1	Respiratory distress syndrome, adult[MH] OR shock lung OR acute respiratory distress syndrome OR adult respiratory distress syndrome
#2	Acute lung injury[MH] OR Acute lung injury OR Acute lung injuries
#3	ARDS OR ALI
#4	#1 OR #2 OR #3
Component 2. Ventilator strategies	
#5	Tidal volume[MH] OR Tidal volumes OR Tidal volume
#6	Respiration, Artificial[MH] OR Artificial respiration OR Mechanical ventilation OR Mechanical ventilations
#7	pressure* limited* OR "volume limited" OR LPVS OR lung protective ventilat*
#8	#5 OR #6 OR #7
#9	#4 AND #8
Component 3. Study design and language limit	
#10	Clinical trial[pt] OR trial[ti] OR randomized controlled trial[pt] OR (controlled clinical trial[pt] OR randomized[tiab]) OR placebo[tiab] OR clinical trials as topic[MH] OR randomly[tiab]
#11	Animals[MH] NOT (Animals[MH] AND Humans[MH])
#12	#10 NOT #11
#13	#9 AND #12

2. CENTRAL

Performed on 2016/05/17

Number	Searched for
Component 1. Included patients	
#1	MeSH descriptor: [Respiratory Distress Syndrome, Adult] explode all trees
#2	acute lung injury
#3	Adult Respiratory Distress Syndrome
#4	Acute Respiratory Distress Syndrome
#5	ARDS or ALI
#6	#1 or #2 or #3 or #4 or #5
Component 2. Ventilator strategies	
#7	MeSH descriptor: [Tidal Volume] explode all tree
#8	artificial near ventilation
#9	tidal volume
#10	protective near ventilation
#11	pressure-limited
#12	LPVS
#13	#7 or #8 or #9 or #10 or #11 or #12
#14	#6 and #13

2. EMBASE

Performed on 2016/6/20

Number	Searched for
Component 1. Included patients	
#1	EMB.EXACT("adult respiratory distress syndrome") OR ("shock lung" OR "human ARDS" OR "acute respiratory distress syndrome" OR "adult respiratory distress syndrome")
#2	EMB.EXACT("acute lung injury") OR ("acute lung injuries" OR "acute lung injury")
#3	TI,AB(ARDS) OR TI,AB(ALI)
#4	#1 OR #2 OR #3
Component 2. Ventilator strategies	
#5	EMB.EXACT.EXPLODE("tidal volume") OR ("tidal volumes" OR "tidal volume")
#6	EMB.EXACT.EXPLODE("artificial ventilation") OR ("artificial respiration" OR "mechanical ventilation" OR "mechanical ventilations")
#7	pressure-limited OR pressure* limited* OR "volume limited" OR LPVS OR lung protective ventilat*
#8	#5 OR #6 OR #7
#9	#4 AND #8
Component 3. Study design	
#10	(EMB.EXACT("controlled clinical trial") OR EMB.EXACT.EXPLODE("clinical trial (topic)") OR EMB.EXACT("randomized controlled trial")) OR (TI,AB(randomized) OR TI,AB(randomly) OR TI(trial) OR TI,AB(placebo))
#11	#9 AND #10
Component 4. Language limit	
#12	#11 NOT (ANIMAL(YES) NOT HUMAN(YES))
#13	#12 AND PD(>=20150401)

3. Ichushi

Performed on 2016/05/17

Number	Searched for
Component 1. Included patients	
#1	呼吸窮迫症候群-急性/TH or ARDS/AL
#2	急性肺損傷/TH or 急性肺損傷/AL
#3	#1 or #2
Component 2. Ventilator strategies	
#4	一回換気量/TH or 一回換気量/AL
#5	人工呼吸/TH or 人工呼吸/AL or レスピレータ装/AL or 機械的換気/AL or 人工換気量/AL or 人工呼吸管理/AL or 人工呼吸法/AL or 人工呼吸療法/AL or 調節呼吸/AL
#6	人工呼吸器/TH or 人工呼吸器/AL or ベンチレータ/AL or ベンチレーター/AL or レスピレータ/AL or レスピレーター/AL or 機械的ベンチレータ/AL or 機械的ベンチレーター/AL or 肺ベンチレータ/AL or 肺ベンチレーター/AL
#7	#4 or #5 or #6
#8	#3 and #7

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item
ADMINISTRATIVE INFORMATION		
Title:		
Identification	p1	Identify the report as a protocol of a systematic review
Update	-	If the protocol is for an update of a previous systematic review, identify as such
Registration	P1 and p5	If registered, provide the name of the registry (such as PROSPERO) and registration number
Authors:		
Contact	P2	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author
Contributions	p16	Describe contributions of protocol authors and identify the guarantor of the review
Amendments	-	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments
Support:		
Sources	p16	Indicate sources of financial or other support for the review
Sponsor	p16	Provide name for the review funder and/or sponsor
Role of sponsor or funder	p16	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol
INTRODUCTION		
Rationale	p7-p8	Describe the rationale for the review in the context of what is already known
Objectives	p9	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)
METHODS		
Eligibility criteria	p9	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review
Information sources	p10	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage
Search strategy	p10-p11	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated
Study records:		
Data management	p11	Describe the mechanism(s) that will be used to manage records and data throughout the review

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

Selection process	p11-p12	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)
Data collection process	p12	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators
Data items	p10	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications
Outcomes and prioritization	p10	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale
Risk of bias in individual studies	p12	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis
Data synthesis	p13	Describe criteria under which study data will be quantitatively synthesised
	p13	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)
	p14	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)
	-	If quantitative synthesis is not appropriate, describe the type of summary planned
Meta-bias(es)	p13-p14	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)
Confidence in cumulative evidence	p14-p15	Describe how the strength of the body of evidence will be assessed (such as GRADE)

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.

BMJ Open

Optimal plateau pressure for patients with acute respiratory distress syndrome: A protocol for a systematic review and meta-analysis with meta-regression

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-015091.R1
Article Type:	Protocol
Date Submitted by the Author:	17-Jan-2017
Complete List of Authors:	Yasuda, Hideto; Kameda Medical Center, Department of Intensive Care Medicine; Keio University School of Medicine, Department of Preventive Medicine and Public Health Nishimura, Tetsuro; National Hospital Organization Osaka National Hospital, Traumatology and Critical Care Medical Center Kamo, Tetsuo; Osaka City University Graduate School of Medicine, Department of Traumatology and Critical Care Medicine Sanui, Masamitsu; Jichi Medical University, Department of Anesthesiology and Critical Care Medicine Nango, Eishu; Tokyo-Kita Medical Center, Department of General Medicine Abe, Takayuki; Keio University Hospital Takebayashi, Toru; Keio University School of Medicine, Department of Preventive Medicine and Public Health Lefor, Alan; Jichi Medical University, Department of Surgery Hashimoto, Satoru; Kyoto Prefectural University of Medicine, Department of Anesthesiology and Intensive Care Medicine
Primary Subject Heading:	Respiratory medicine
Secondary Subject Heading:	Evidence based practice, Intensive care
Keywords:	acute respiratory distress syndrome, ARDS, mechanical ventilation, plateau pressure

SCHOLARONE™
Manuscripts

1
2
3
4 Title

5
6
7 Optimal plateau pressure for patients with acute respiratory distress syndrome: A protocol for a
8
9
10 systematic review and meta-analysis with meta-regression
11

12
13
14
15
16
17 Registration

18
19
20 Protocol and registration: We registered this protocol to this journal and PROSPERO (registration
21
22
23 number is: CRD42016041924).
24
25

26
27
28
29 Authors

30
31
32
33 Hideto Yasuda, MD^{1,2}, Tetsuro Nishimura, MD³, Tetsuro Kamo, MD⁴, Masamitsu Sanui, MD, PhD⁵,
34
35
36 Eishu Nango, MD⁶, Takayuki Abe, PhD^{2,7}, Toru Takebayashi, MD, PhD², Satoru Hashimoto, MD,
37
38
39 PhD⁹ and Alan Kawarai Lefor MD MPH PhD⁸
40
41
42
43
44
45

- 46 1. Department of Intensive Care Medicine, Kameda Medical Center, Chiba, Japan
47
48
49 2. Department of Preventive Medicine and Public Health, Keio University School of Medicine,
50
51
52 Tokyo, Japan
53
54
55 3. Department of Traumatology and Critical Care Medicine, Osaka City University Graduate School
56
57
58
59
60

1
2
3
4 of Medicine, Osaka, Japan
5
6

7 4. Department of Respiratory Medicine, Keio University School of Medicine, Tokyo, Japan
8
9

10 5. Department of Anesthesiology and Critical Care Medicine, Jichi Medical University Saitama
11
12

13 Medical Center, Saitama, Japan
14
15

16 6. Department of General Medicine, Tokyo-Kita Medical Center, Tokyo, Japan
17
18

19 7. Biostatistics Unit at Clinical and Translational Research Center, Keio University Hospital, Tokyo,
20
21

22 Japan
23
24

25 8. Department of Surgery, Jichi Medical University, Tochigi, Japan
26
27

28 9. Department of Anesthesiology and Intensive Care, Kyoto Prefectural University of Medicine,
29
30

31 Kyoto, Japan
32
33

34
35
36
37
38
39 Corresponding author
40

41 Satoru Hashimoto, Department of Anesthesiology and Intensive Care, Kyoto Prefectural University of
42
43

44 Medicine, Kyoto, Japan
45
46

47
48 Kawaramachi-Hirokoji Kajii-cho 465, Kamigyo, Kyoto, Japan 602-8566
49
50

51
52 Phone 81/75-251-5725 FAX 81/75-251-5843
53
54

55 satoru@koto.kpu-m.ac.jp
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Key words: acute respiratory distress syndrome, ARDS, mechanical ventilation, plateau pressure

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2016-015091 on 29 May 2017. Downloaded from <http://bmjopen.bmj.com/> on April 17, 2024 by guest. Protected by copyright.

1
2
3
4 Abstract

5
6
7 Introduction: Lower tidal volume ventilation in patients with acute respiratory distress syndrome
8
9
10 (ARDS) is a strategy to reduce the plateau pressure and driving pressure to limit ventilator induced
11
12
13 lung injury (VILI). Several randomized controlled trials (RCTs) and meta-analyses showed that
14
15
16 limiting both the plateau pressure and the tidal volume decreased mortality, but the optimal plateau
17
18
19 pressure to demonstrate a benefit is uncertain. The aim of this systematic review is to investigate the
20
21
22 optimal upper limit of plateau pressure in patients with ARDS to prevent VILI and improve clinical
23
24
25 outcomes using meta-analysis with and without meta-regression.
26
27

28
29
30 Methods and analysis: RCTs comparing two mechanical ventilation strategies will be included, with
31
32
33 lower plateau pressure and with higher plateau pressure, among patients with ARDS and acute lung
34
35
36 injury. Data sources include MEDLINE via the NCBI Entrez system, Cochrane Central Register of
37
38
39 Controlled Trials (CENTRAL), EMBASE and Ichushi, a database of papers in Japanese. Two of three
40
41
42 physicians will independently screen trials obtained by search for eligibility, and extract data from
43
44
45 included studies onto standardized data recording forms. For each included trial, the risk of bias and
46
47
48 the quality of evidence will be evaluated using the Grading of Recommendation Assessment
49
50
51 Development and Evaluation (GRADE) system.
52
53

54
55
56 Ethics and dissemination: This study does not require ethical approval. The results of this systematic
57
58
59
60

1
2
3
4 review and meta-analysis with and without meta-regression will be disseminated through conference
5
6
7 presentation and publication in a peer-reviewed journal.
8
9

10 Trial registration number: CRD42016041924
11
12
13

14 Strengths and limitations of this study 15 16

- 17
18 • One strength of this study is that it is a systematic review with meta-regression analysis comparing
19
20 different plateau pressures to investigate the upper limit of plateau pressure for patients with
21
22 ARDS undergoing mechanical ventilation.
23
24
25
26
27
28
- 29 • One limitation of the study is the paucity of available data regarding the trans-pulmonary pressure
30
31 although it is also important to compare the trans-pulmonary pressure in addition to the plateau
32
33 pressure. We have to wait for future available studies.
34
35
36
37
38
- 39 • This is a protocol article. The results of the subsequent systematic review and meta-analysis with
40
41 meta-regression analysis will be prepared separately.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Acute respiratory distress syndrome (ARDS) is a common life-threatening disorder in critically ill patients with 30-60% mortality (1-3). ARDS is usually accompanied by short- and long-term morbidities including prolonged stay in the intensive care unit, prolonged ventilator dependence, various neuropsychological impairments (e.g. depression, cognitive decline) and decreased quality of life (2, 4, 5).

The most critical factor associated with the high mortality in patients with ARDS is ventilator induced lung injury (VILI)(6) although VILI can also develop in patients with non-injured lung(7). Patients with ARDS and low lung compliance receiving mechanical ventilation (MV) may develop VILI, including regional alveolar over-distension, repetitive cycling alveolar collapse with shear stress (atelectrauma) aggravated by a high concentration of inspired oxygen, (8-11). VILI can lead to not only an extended time needed for liberation from MV, but also an increase in mortality.

For the purpose of minimizing VILI, a substantial number of ventilator strategies have been proposed (12-19). Lower tidal volume (6 ml/kg per predicted body weight) ventilation is a strategy to reduce plateau pressure and driving pressure, roughly reflecting the level of alveolar over-distension (14). Several randomized controlled trials (RCTs) and meta-analyses have shown a beneficial effect of pressure and volume-limited ventilation strategies on clinical outcomes in patients with ARDS (14, 15,

1
2
3
4 20-27). In the Scandinavian clinical practice guideline 2014 (21), developed with a Cochrane
5
6
7 systematic review (20), it is strongly recommended that airway pressure and tidal volume should be
8
9
10 limited. In the Surviving Sepsis Campaign Guideline 2012 (28), it is recommended that plateau
11
12
13 pressure should be measured and maintained below 30cmH₂O during the time of passive pulmonary
14
15
16 expansion. However, Villar et al(19) have recently reported in an observational study that a Pplat
17
18
19 above 26 cmH₂O is harmful, which suggest that appropriate plateau pressure still remains to be
20
21
22 investigated.
23
24

25
26
27 However, the Cochrane review (20) was a comparison between two lung ventilation
28
29
30 strategies, protective and non-protective, not a comparison of different cutoff limits of plateau
31
32
33 pressures. All RCTs included in the meta-analysis (16) performed a comparison of higher and lower
34
35
36 levels of the upper limits of plateau pressures, but no studies compared various levels of plateau
37
38
39 pressures. Also, interactions between the time course and changes in plateau pressure were not
40
41
42 considered in the meta-analysis(16). Furthermore, the relationship between the plateau pressure and
43
44
45 mortality in ARDS may not be linear(29), it may be difficult to investigate the optimal upper limit of
46
47
48 plateau pressure by a simple comparison of two different plateau pressures. Therefore, to investigate
49
50
51 the optimal upper limit of plateau pressure during the course of ARDS, a simple meta-analysis of
52
53
54
55
56 RCTs seems to be insufficient. Stratification by the upper limit of plateau pressure and by the day on
57
58
59
60

1
2
3
4 ventilators along with regression analysis using a meta-regression analysis may be effective.
5
6

7 Objective

8
9
10 The objective of this systematic review is to investigate the optimal limit of plateau
11
12 pressure on a different day on ventilators to improve clinical outcomes associated with VILI in
13
14 patients with ARDS.
15
16
17
18
19

20 Methods and analyses

21
22
23 This systematic review is designed following the Preferred Reporting Items for Systematic
24
25 review and Meta-Analyses (PRISMA) statements (30). The logistics and reporting of this protocol will
26
27 be in compliance with the PRISMA-P. This protocol is registered with PROSPERO prospective
28
29 register of systematic reviewers (registration number is: CRD42016041924).
30
31
32
33
34
35
36
37
38

39 Study Eligibility

40
41
42 Type of studies: We will include only published RCTs, either full scale or as pilot studies.
43
44

45
46 Type of participants: The study will include adults with ARDS or acute lung injury (ALI) from any
47
48 cause, as defined by the North-American-European Consensus Conference on ARDS (NAECC), age
49
50 18years or older, undergoing MV (31).
51
52
53
54

55
56 Type of interventions and comparators: We will include RCTs which compared two different MV
57
58
59
60

1
2
3
4 strategies, with a lower plateau pressure and a higher plateau pressure, among patients with ARDS and
5
6
7 ALI. We will conduct sub-group analyses of the plateau pressures stratified by the day of measuring
8
9
10 plateau pressure in addition to a primary meta-analysis which does not consider ventilator day.
11
12

13
14 Type of outcomes: The following outcome measures will be evaluated: the primary outcome is
15
16 short-time mortality (1. at the end of the follow up period for each trial, 2. at day 28, and 3. at the
17
18 hospital discharge), and secondary outcomes are the number of ventilator-free days up to 28 days and
19
20 barotrauma during hospitalization.
21
22
23
24

25 26 Information sources

27
28
29 We searched MEDLINE via the NCBI Entrez system, the Cochrane Central Register of
30
31 Controlled Trials (CENTRAL), EMBASE and Ichushi, a database including papers in Japanese.
32
33
34

35 36 Search strategy

37
38
39 We used the search keywords “Mechanical ventilation” AND “ARDS”, “adult respiratory
40
41 distress syndrome”, “ALI” or “acute lung injury” AND “tidal volume”, “pressure limited” or “volume
42
43 limited”. We also performed a MeSH term search using the following terms: “respiratory distress
44
45 syndrome, adult”, or “acute lung injury” AND “tidal volume”, or “respiration, artificial”. Searches
46
47
48 were performed in May or June 2016. The detailed strategy and details of the dates performed are
49
50
51 shown in Table 1.
52
53
54
55
56
57
58
59
60

Study records and Data management

The literature search results from each database will be extracted into Microsoft (Redmond WA USA) Excel files and duplicates will be removed by being sorted alphabetically based on author.

The results of all processes (first screening and second screening) are recorded to the same data file.

All full text files will be managed with EndNote (X7) bibliographic software (Thompson Reuters, Philadelphia, Pennsylvania, USA). A meta-analysis will be conducted with the Review Manager (RevMan) software V.5.3.5. All data will be managed by the primary investigator HY.

Selection process

Two of three physicians (HY, TN, TK) will screen titles and abstracts during the first screening and the full text during the second screening for relevant studies, and will independently extract data from included studies into standardized data forms. Disagreements are resolved by discussion with one of the three physicians who did not screen the study. EN supervises the process of systematic review. TA supervises the process of analysis as a biostatistician. MS, TT and SH are consultants on clinically relevant issues.

Data collection process

After extracting studies for meta-analyses during the second screening, data will be extracted from each study by three reviewers (HY, TN, TK) using two tools: (1) the Cochrane Data

1
2
3
4 Collection Form (RCTs only) (32) and (2) Review Manager (RevMan) software V.5.3.5(33).
5
6

7 Risk of bias in individual studies
8
9

10 The risk of bias in each included study will be evaluated with the Cochrane Risk of Bias
11
12 Assessment tool (34, 35) with respect to the following eight domains: (a) random sequence generation,
13
14 (b) allocation concealment, (c) blinding of participants and personnel, (d) blinding of outcome
15
16 assessors, (e) incomplete outcome data, (f) selective outcome reporting and (g) other sources of bias.
17
18
19

20 Each bias will be graded as either 'low-risk', 'unclear-risk' or 'high-risk'. Two of three reviewers (HY,
21
22 TN, TK) will separately grade the bias of each study, and any disagreement will be resolved by a
23
24 decision from the remaining reviewer.
25
26
27
28
29
30
31

32 Data synthesis
33
34

35 Forest plots will be used for the meta-analysis, and effect size will be expressed as relative
36
37 risk with 95% confidence interval [CI] for categorical data and as weighted mean differences with
38
39 95% CI for continuous data. Outcome measures will be pooled using a random effect model to take
40
41 into account study-specific effects in measures. For all analyses, a two-sided p-value < 0.05 is
42
43 considered significant. In case of missing data, we will attempt to contact the authors of the study for
44
45 additional data. If a reply from the authors is not obtained, we will classify it as missing data.
46
47
48
49
50
51
52
53
54

55 Meta-regression analysis will be conducted to evaluate the association between outcome
56
57
58
59
60

1
2
3
4 measures and covariates, and to determine the cut-off of the plateau pressure affecting the outcomes
5
6
7 adjusted with covariates, such as the different kinds of ventilation methods, the day of plateau pressure
8
9
10 measurement and severity of ARDS for the evaluation. Meta-regression analysis will be performed
11
12
13 with R version 3.3.2.
14

15 16 17 18 19 20 Assessment of heterogeneity

21
22 Study heterogeneity between trials for each outcome will be assessed with an I^2 statistic for
23
24 quantifying inconsistency (RevMan). I^2 values of <25%, 25%-50% and >50% represent small,
25
26 medium and large amounts of heterogeneity, respectively (36). Subgroup analysis, meta-regression
27
28 analysis and sensitivity analysis will be performed for evaluating possible sources of heterogeneity
29
30
31 when sufficient data are available.
32
33
34
35
36
37
38

39 Assessment of reporting bias

40
41 A funnel plot will be used to investigate the possibility of publication bias if ≥ 10 studies
42
43 are available (RevMan) (37). To test for funnel plot asymmetry, we will use the Egger test (38) for
44
45
46 continuous outcomes and the arcsine test (39) for dichotomous outcomes.
47
48
49
50

51 Subgroup analysis and sensitivity analysis

52
53
54
55 Subgroup analysis is planned based on the main factors that may cause heterogeneity,
56
57
58
59
60

1
2
3
4 which are the levels of plateau pressure. Subgroup analysis will also be performed for different timing
5
6
7 of plateau pressure measured during MV. We are also planning subgroup analyses after stratification
8
9
10 according to ventilator strategies and modes.
11

12
13 For sensitivity analysis, we will first exclude all studies that are assessed as having a high
14
15 risk of bias. High risk of bias in each study will be determined when the quality of evidence of each
16
17 study will be assessed as “low” or “very low”. The remaining studies will be used for sensitivity
18
19 analysis.
20
21
22
23
24

25 26 Assessment of confidence in cumulative evidence 27

28
29 We will evaluate the quality of evidence for these studies, using the Grading of
30
31 Recommendation Assessment Development and Evaluation (GRADE) system (40). The quality of
32
33 evidence will be decreased by any one of the following limitations: risk of bias, imprecision,
34
35 inconsistency, indirectness and publication bias. Based on this assessment, the quality of evidence for
36
37 each outcome will be assessed as ‘high’, ‘moderate’, ‘low’ or ‘very low’ (GRADEpro, McMaster
38
39 University, 2014). Two of three reviewers (HY, TN, TK) will separately grade the quality of evidence
40
41
42
43
44
45
46 of each study, and any disagreement will be resolved by a decision of the remaining reviewer.
47
48
49
50

51 52 53 54 55 Authors' contributions 56 57 58 59 60

1
2
3
4 HY contributed in the study concept and design, screening for relevant studies, and drafting of the
5
6
7 manuscript. TN and TK contributed to the study concept and design, screening for relevant studies.
8
9

10 MS contributed to the study concept and design, and critical revision of the manuscript for important
11
12 intellectual content. AKL contributed to critical revision of the manuscript for important intellectual
13
14 content. EN supervised the process of systematic review. TA supervised the process of analysis as a
15
16
17 biostatistician. TT, AKL and SH were consultants on clinically relevant issues.
18
19
20
21
22
23
24
25

26 Funding sources/sponsors
27

28
29 None
30
31
32
33
34
35

36 Conflicts of interest
37

38
39 No one has conflicts of interest in the study.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. *N Engl J Med* 2005;353:1685-93.
2. Rubenfeld GD, Herridge MS. Epidemiology and outcomes of acute lung injury. *Chest* 2007;131:554-62.
3. Bersten AD, Edibam C, Hunt T, et al. Incidence and mortality of acute lung injury and the acute respiratory distress syndrome in three Australian States. *Am J Respir Crit Care Med* 2002;165:443-8.
4. Herridge MS, Tansey CM, Matte A, et al. Functional disability 5 years after acute respiratory distress syndrome. *N Engl J Med* 2011;364:1293-1304.
5. Davidson TA, Caldwell ES, Curtis JR, et al. Reduced quality of life in survivors of acute respiratory distress syndrome compared with critically ill control patients. *JAMA* 1999;281:354-60.
6. Amato MB, Meade MO, Slutsky AS, et al. Driving pressure and survival in the acute respiratory distress syndrome. *N Engl J Med* 2015;372:747-55.
7. Sutherasan Y, Vargas M, Pelosi P. Protective mechanical ventilation in the non-injured lung: review and meta-analysis. *Crit Care* 2014;18:211.
8. Gattinoni L, Pesenti A, Avalli L, et al. Pressure-volume curve of total respiratory system in acute respiratory failure. Computed tomographic scan study. *Am Rev Respir Dis* 1987;136:730-6.
9. Dreyfuss D, Soler P, Basset G, et al. High inflation pressure pulmonary edema. Respective effects of high airway pressure, high tidal volume, and positive end-expiratory pressure. *Am Rev Respir Dis* 1988;137:1159-64.
10. Muscedere JG, Mullen JB, Gan K, et al. Tidal ventilation at low airway pressures can augment lung injury. *Am J Respir Crit Care Med* 1994;149:1327-34.
11. Caironi P, Cressoni M, Chiumello D, et al. Lung opening and closing during ventilation of acute respiratory distress syndrome. *Am J Respir Crit Care Med* 2010;181:578-86.
12. Ferguson ND, Cook DJ, Guyatt GH, et al. High-frequency oscillation in early acute respiratory distress syndrome. *N Engl J Med* 2013;368:795-805.
13. Young D, Lamb SE, Shah S, et al. High-frequency oscillation for acute respiratory distress syndrome. *N Engl J Med* 2013;368:806-13.
14. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute

- 1
2
3 respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. *N*
4 *Engl J Med* 2000;342:1301-08.
- 5
6 15. Meade MO, Cook DJ, Guyatt GH, et al. Ventilation strategy using low tidal
7 volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute
8 lung injury and acute respiratory distress syndrome: a randomized controlled trial.
9 *JAMA* 2008;299:637-45.
- 10
11 16. Kacmarek RM, Villar J, Sulemanji D, et al. Open Lung Approach for the Acute
12 Respiratory Distress Syndrome: A Pilot, Randomized Controlled Trial. *Crit Care Med*
13 2016;44:32-42.
- 14
15 17. Fish E, Novack V, Banner-Goodspeed VM, et al. The Esophageal Pressure-Guided
16 Ventilation 2 (EPVent2) trial protocol: a multicentre, randomised clinical trial of mechanical
17 ventilation guided by transpulmonary pressure. *BMJ Open* 2014;4:e006356.
- 18
19 18. Talmor D, Sarge T, Malhotra A, et al. Mechanical ventilation guided by esophageal pressure
20 in acute lung injury. *N Engl J Med* 2008;359:2095-04.
- 21
22 19. Villar J, Ambros A, Soler JA, et al. Age, PaO₂/FIO₂, and Plateau Pressure Score: A
23 Proposal for a Simple Outcome Score in Patients With the Acute Respiratory Distress Syndrome. *Crit*
24 *Care Med* 2016;44:1361-9.
- 25
26 20. Petrucci N, De Feo C. Lung protective ventilation strategy for the acute
27 respiratory distress syndrome. *Cochrane Database Syst Rev* 2013:CD003844.
- 28
29 21. Claesson J, Freundlich M, Gunnarsson I, et al. Scandinavian clinical practice
30 guideline on mechanical ventilation in adults with the acute respiratory distress
31 syndrome. *Acta Anaesthesiol Scand* 2015;59:286-97.
- 32
33 22. Fuller BM, Mohr NM, Drewry AM, et al. Lower tidal volume at initiation of
34 mechanical ventilation may reduce progression to acute respiratory distress syndrome: a
35 systematic review. *Crit Care* 2013;17:R11.
- 36
37 23. Burns KE, Adhikari NK, Slutsky AS, et al. Pressure and volume limited
38 ventilation for the ventilatory management of patients with acute lung injury: a
39 systematic review and meta-analysis. *PLoS One* 2011;6:e14623.
- 40
41 24. Moran JL, Bersten AD, Solomon PJ. Meta-analysis of controlled trials of
42 ventilator therapy in acute lung injury and acute respiratory distress syndrome: an
43 alternative perspective. *Intensive Care Med* 2005;31:227-35.
- 44
45 25. Brochard L, Roudot-Thoraval F, Roupie E, et al. Tidal volume reduction for
46 prevention of ventilator-induced lung injury in acute respiratory distress syndrome. The
47 Multicenter Trial Group on Tidal Volume reduction in ARDS. *Am J Respir Crit Care Med*
48 1998;158:1831-8.
- 49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 26. Brower RG, Shanholtz CB, Fessler HE, et al. Prospective, randomized,
4 controlled clinical trial comparing traditional versus reduced tidal volume ventilation in
5 acute respiratory distress syndrome patients. *Crit Care Med* 1999;27:1492-8.
6
7
8 27. Villar J, Kacmarek RM, Perez-Mendez L, et al. A high positive end-expiratory
9 pressure, low tidal volume ventilatory strategy improves outcome in persistent acute
10 respiratory distress syndrome: a randomized, controlled trial. *Crit Care Med*
11 2006;34:1311-8.
12
13
14 28. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign:
15 international guidelines for management of severe sepsis and septic shock, 2012.
16 *Intensive Care Med* 2013;39:165-228.
17
18
19 29. Laffey JG, Bellani G, Pham T, et al. Potentially modifiable factors contributing to outcome
20 from acute respiratory distress syndrome: the LUNG SAFE study. *Intensive Care Med*
21 2016;42:1865-76.
22
23
24 30. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic
25 review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ*
26 2015;349:g7647.
27
28
29 31. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus
30 Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial
31 coordination. *Am J Respir Crit Care Med* 1994;149:818-24.
32
33
34 32. Collaboration. TC. Data Collection Form-Intervention
35 review for RCTs only. Secondary Data Collection Form-Intervention
36 review for RCTs only.
37 <<http://training.cochrane.org/resource/data-collection-forms-intervention-reviews>>
38 Accessed 7 November 2016
39
40
41 33. Collaboration. TC. RevMan 5 Download and Installion.
42 Secondary RevMan 5 Download and Installion.
43 <<http://tech.cochrane.org/revman/download>>Accessed 7 November 2016
44
45
46 34. Collaboration. TC. Cochrane Handbook for Systematic
47 Reviews of Interventions. < <http://training.cochrane.org/handbook> > Accessed 7
48 November 2016
49
50
51 35. Collaboration. TC. Table 8.5.d: Criteria for judging risk of
52 bias in the 'Risk of bias' assessment tool. <
53 [http://handbook.cochrane.org/chapter_8/table_8_5_d_criteria_for_judging_risk_of_bi](http://handbook.cochrane.org/chapter_8/table_8_5_d_criteria_for_judging_risk_of_bias_in_the_risk_of.htm)
54 [as_in_the_risk_of.htm](http://handbook.cochrane.org/chapter_8/table_8_5_d_criteria_for_judging_risk_of_bias_in_the_risk_of.htm) >Accessed 7 November 2016
55 [for_judging_risk_of_bias_in_the_risk_of.htm](http://handbook.cochrane.org/chapter_8/table_8_5_d_criteria_for_judging_risk_of_bias_in_the_risk_of.htm).2011
56
57
58
59
60

- 1
2
3 36. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat*
4 *Med* 2002;21:1539-58.
5
6 37. Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and
7 interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials.
8 *BMJ* 2011;343:d4002.
9
10 38. Davey Smith G, Egger M. Meta-analyses of randomised controlled trials. *Lancet*
11 1997;350:1182.
12
13 39. Rucker G, Schwarzer G, Carpenter J. Arcsine test for publication bias in
14 meta-analyses with binary outcomes. *Stat Med* 2008;27:746-63.
15
16 40. Guyatt GH, Oxman AD, Schunemann HJ, et al. GRADE guidelines: a new
17 series of articles in the *Journal of Clinical Epidemiology*. *J Clin Epidemiol* 2011;64:380-2.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 Search strategy

1. MEDLINE

Performed on 2016/05/17

Number	Searched for
Component 1. Included patients	
#1	Respiratory distress syndrome, adult[MH] OR shock lung OR acute respiratory distress syndrome OR adult respiratory distress syndrome
#2	Acute lung injury[MH] OR Acute lung injury OR Acute lung injuries
#3	ARDS OR ALI
#4	#1 OR #2 OR #3
Component 2. Ventilator strategies	
#5	Tidal volume[MH] OR Tidal volumes OR Tidal volume
#6	Respiration, Artificial[MH] OR Artificial respiration OR Mechanical ventilation OR Mechanical ventilations
#7	pressure* limited* OR "volume limited" OR LPVS OR lung protective ventilat*
#8	#5 OR #6 OR #7
#9	#4 AND #8
Component 3. Study design and language limit	
#10	Clinical trial[pt] OR trial[ti] OR randomized controlled trial[pt] OR (controlled clinical trial[pt] OR randomized[tiab]) OR placebo[tiab] OR clinical trials as topic[MH] OR randomly[tiab]
#11	Animals[MH] NOT (Animals[MH] AND Humans[MH])
#12	#10 NOT #11
#13	#9 AND #12

2. CENTRAL

Performed on 2016/05/17

Number	Searched for
Component 1. Included patients	
#1	MeSH descriptor: [Respiratory Distress Syndrome, Adult] explode all trees
#2	acute lung injury
#3	Adult Respiratory Distress Syndrome
#4	Acute Respiratory Distress Syndrome
#5	ARDS or ALI
#6	#1 or #2 or #3 or #4 or #5
Component 2. Ventilator strategies	
#7	MeSH descriptor: [Tidal Volume] explode all tree
#8	artificial near ventilation
#9	tidal volume
#10	protective near ventilation
#11	pressure-limited
#12	LPVS
#13	#7 or #8 or #9 or #10 or #11 or #12
#14	#6 and #13

3. EMBASE

Performed on 2016/6/20

Number	Searched for
Component 1. Included patients	
#1	EMB.EXACT("adult respiratory distress syndrome") OR ("shock lung" OR "human ARDS" OR "acute respiratory distress syndrome" OR "adult respiratory distress syndrome")
#2	EMB.EXACT("acute lung injury") OR ("acute lung injuries" OR "acute lung injury")
#3	TI,AB(ARDS) OR TI,AB(ALI)
#4	#1 OR #2 OR #3
Component 2. Ventilator strategies	
#5	EMB.EXACT.EXPLODE("tidal volume") OR ("tidal volumes" OR "tidal volume")
#6	EMB.EXACT.EXPLODE("artificial ventilation") OR ("artificial respiration" OR "mechanical ventilation" OR "mechanical ventilations")
#7	pressure-limited OR pressure* limited* OR "volume limited" OR LPVS OR lung protective ventilat*
#8	#5 OR #6 OR #7
#9	#4 AND #8
Component 3. Study design	
#10	(EMB.EXACT("controlled clinical trial") OR EMB.EXACT.EXPLODE("clinical trial (topic)") OR EMB.EXACT("randomized controlled trial")) OR (TI,AB(randomized) OR TI,AB(randomly) OR TI(trial) OR TI,AB(placebo))
#11	#9 AND #10
Component 4. Language limit	
#12	#11 NOT (ANIMAL(YES) NOT HUMAN(YES))
#13	#12 AND PD(>=20150401)

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

4. Ichushi

Performed on 2016/05/17

Number	Searched for
Component 1. Included patients	
#1	呼吸窮迫症候群-急性/TH or ARDS/AL
#2	急性肺損傷/TH or 急性肺損傷/AL
#3	#1 or #2
Component 2. Ventilator strategies	
#4	一回換気量/TH or 一回換気量/AL
#5	人工呼吸/TH or 人工呼吸/AL or レスピレータ装/AL or 機械的換気/AL or 人工換気量/AL or 人工呼吸管理/AL or 人工呼吸法/AL or 人工呼吸療法/AL or 調節呼吸/AL
#6	人工呼吸器/TH or 人工呼吸器/AL or ベンチレータ/AL or ベンチレーター/AL or レスピレータ/AL or レスピレーター/AL or 機械的ベンチレータ/AL or 機械的ベンチレーター/AL or 肺ベンチレータ/AL or 肺ベンチレーター/AL
#7	#4 or #5 or #6
#8	#3 and #7

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item
ADMINISTRATIVE INFORMATION		
Title:		
Identification	p1	Identify the report as a protocol of a systematic review
Update	-	If the protocol is for an update of a previous systematic review, identify as such
Registration	P1 and p5	If registered, provide the name of the registry (such as PROSPERO) and registration number
Authors:		
Contact	P2	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author
Contributions	p16	Describe contributions of protocol authors and identify the guarantor of the review
Amendments	-	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments
Support:		
Sources	p16	Indicate sources of financial or other support for the review
Sponsor	p16	Provide name for the review funder and/or sponsor
Role of sponsor or funder	p16	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol
INTRODUCTION		
Rationale	p7-p8	Describe the rationale for the review in the context of what is already known
Objectives	p9	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)
METHODS		
Eligibility criteria	p9	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review
Information sources	p10	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage
Search strategy	p10-p11	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated
Study records:		
Data management	p11	Describe the mechanism(s) that will be used to manage records and data throughout the review

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

Selection process	p11-p12	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)
Data collection process	p12	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators
Data items	p10	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications
Outcomes and prioritization	p10	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale
Risk of bias in individual studies	p12	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis
Data synthesis	p13	Describe criteria under which study data will be quantitatively synthesised
	p13	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)
	p14	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)
	-	If quantitative synthesis is not appropriate, describe the type of summary planned
Meta-bias(es)	p13-p14	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)
Confidence in cumulative evidence	p14-p15	Describe how the strength of the body of evidence will be assessed (such as GRADE)

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.